Voriconazole‐Associated Periostitis: New Insights into Pathophysiology and Management
JBMR Plus, 2022 Voriconazole‐associated periostitis (VAP) is an underrecognized and unpredictable side effect of long‐term voriconazole therapy. We report two cases of VAP occurring in the post‐transplant setting: a 68‐year‐old lung transplant recipient who required ...
Michael J Bennett +9 more
doaj +2 more sources
Drug, Healthcare and Patient Safety, 2017 Martin J Ferguson,1 Maria L Randles,2 Declan G de Freitas3 1Pharmacy Department, Beaumont Hospital, Beaumont, Dublin, 2Pharmacy Department, Wexford General Hospital, Wexford, 3Department of Transplantation, Urology and Nephrology, Beaumont Hospital ...
Ferguson MJ, Randles ML, de Freitas DG
doaj +1 more source
Central Nervous System Aspergillosis: Advances in Diagnosis, Therapeutics, and Multidisciplinary Management (2026 Update). [PDF]
MycosesABSTRACT Background Central nervous system (CNS) aspergillosis is a life‐threatening infection with mortality rates exceeding 50%, especially in immunocompromised patients. Significant challenges persist due to limited antifungal drug penetration into the CNS, emerging resistance, and diagnostic delays, despite advancements in therapy and diagnostics ...
Mansour MA +5 more
europepmc +2 more sources
CAQ Corner: Basic concepts of transplant immunology
, 2022 Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley +1 more source
Quantification of voriconazole in plasma by liquid chromatography-tandem mass spectrometry [PDF]
, 2005 A convenient liquid chromatography-tandem mass spectrometry method for the quantification of the triazole antifungal agent voriconazole in plasma samples is described. Fenbuconazole is used as an internal standard.
Spöhrer, Ute +2 more
core +1 more source
A Multifactorial Azole Response in Clinically Relevant Fusarium Species Complexes. [PDF]
MycosesABSTRACT Background Fusarium spp. are clinically relevant filamentous fungi with intrinsically low susceptibility to multiple antifungal agents, particularly azoles, and are included in the World Health Organization fungal priority pathogens list.
Grizante Barião PH +5 more
europepmc +2 more sources
In Vitro Pharmacokinetic/Pharmacodynamic Modeling of Voriconazole Activity against Aspergillus Species in a New In Vitro Dynamic Model [PDF]
, 2012 The pharmacodynamics (PD) of voriconazole activity against Aspergillus spp. were studied using a new in vitro dynamic model simulating voriconazole human pharmacokinetics (PK), and the PK-PD data were bridged with human drug exposure to assess the ...
Zerva, Loukia +4 more
core +1 more source
Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial [PDF]
, 2023 Objectives: Voriconazole therapeutic drug monitoring (TDM) is recommended based on retrospective data and limited prospective studies. This study aimed to investigate whether TDM-guided voriconazole treatment is superior to standard treatment for ...
Voriconazole ZonMw Study Group
core
Equine Fungal Keratitis due to Cladorrhinum bulbillosum. [PDF]
Vet OphthalmolABSTRACT Objective To describe the case details and treatment of an equine fungal keratitis case caused by Cladorrhinum bulbillosum. Animal Studied A 14‐year‐old Bashkir Curly gelding with a complicated corneal ulcer of the left eye. Procedures Corneal cytology was performed, and intraoperative samples were collected for polymerase chain reaction and ...
Hamilton A, Lacy L, Scherrer N.
europepmc +2 more sources
Pharmacodynamic Effects of Simulated Standard Doses of Antifungal Drugs against Aspergillus Species in a New In Vitro Pharmacokinetic/Pharmacodynamic Model [PDF]
, 2011 In conventional MIC tests, fungi are exposed to constant drug concentrations, whereas in vivo, fungi are exposed to changing drug concentrations.
Thomas J. Walsh +11 more
core +1 more source